Identification
NamePrednisolone
Accession NumberDB00860  (APRD00197)
TypeSmall Molecule
GroupsApproved, Vet Approved
Description

A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]

Structure
Thumb
Synonyms
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
Hydroretrocortine
Metacortandralone
PRDL
Prednisolona
Prednisolonum
External IDs NSC-9120 / NSC-9900
Product Ingredients
IngredientUNIICASInChI KeyDetails
Prednisolone 21-phosphate752SY38R6C 302-25-0JDOZJEUDSLGTLU-VWUMJDOOSA-NDetails
Prednisolone acetate8B2807733D 52-21-1LRJOMUJRLNCICJ-JZYPGELDSA-NDetails
Prednisolone sodium phosphateIV021NXA9J 125-02-0VJZLQIPZNBPASX-WFFZFITINA-LDetails
prednisolone sodium succinate8223RR9DWF 1715-33-9FKKAEMQFOIDZNY-CODXZCKSSA-MDetails
Prednisolone tebutate1V7A1U282K 7681-14-3HUMXXHTVHHLNRO-KAJVQRHHSA-NDetails
Prednisolone tertiary butylacetateNot AvailableNot AvailableNot applicableDetails
Product Images
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ak Tate Oph Sus 1%Suspension1 %OphthalmicSandoz Canada Incorporated1985-12-312008-08-07Canada
Diopred Suspension 1%Suspension1 %OphthalmicSandoz Canada Incorporated1994-12-31Not applicableCanada
Flo-predSuspension15 mg/5mLOralTaro Pharmaceuticals U.S.A., Inc.2008-01-17Not applicableUs
Inflamase Forte Oph Soln 1%Liquid10 mgOphthalmicIolab Pharmaceuticals1988-12-311996-09-09Canada
Inflamase Forte Ophthalmic Solution 1%Solution1 %OphthalmicNovartis Ophthalmics Novartis Pharmaceuticals (Canada) Inc1996-08-202004-07-13Canada
Inflamase MildLiquid.125 %OphthalmicNovartis Ophthalmics Novartis Pharmaceuticals (Canada) Inc1995-12-312002-07-04Canada
Inflamase Oph Soln 0.125%Liquid1.25 mgOphthalmicIolab Pharmaceuticals1988-12-311996-09-09Canada
Minims Prednisolone Sodium Phosphate 0.5%Solution / drops0.5 %Ophthalmic; TopicalValeant Canada Lp Valeant Canada S.E.C.1995-12-31Not applicableCanada
Novo-prednisolone 5mgTablet5 mgOralNovopharm Limited1967-12-312005-08-10Canada
OmnipredSuspension10 mg/mLOphthalmicAlcon, Inc.2007-11-06Not applicableUs
Orapred ODTTablet, orally disintegrating15 mg/1OralConcordia Pharmaceuticals, Inc2006-06-01Not applicableUs
Orapred ODTTablet, orally disintegrating30 mg/1OralShionogi2006-06-012016-10-13Us59630 0702 48 nlmimage10 1e1b8f7c
Orapred ODTTablet, orally disintegrating15 mg/1OralShionogi2006-06-012016-10-13Us59630 0701 48 nlmimage10 d916ec97
Orapred ODTTablet, orally disintegrating30 mg/1OralConcordia Pharmaceuticals, Inc2006-06-01Not applicableUs
Orapred ODTTablet, orally disintegrating10 mg/1OralConcordia Pharmaceuticals, Inc2006-06-01Not applicableUs
Orapred ODTTablet, orally disintegrating10 mg/1OralShionogi2006-06-012016-10-13Us
PediapredLiquid5 mgOralSanofi Aventis1998-09-23Not applicableCanada
PediapredSolution5 mg/5mLOralRoyal Pharmaceuticals2017-07-14Not applicableUs
Pediapred - Liq 6.7mg/5mlLiquid5 mgOralFisons1995-12-311998-08-12Canada
PMS-prednisoloneSolution5 mgOralPharmascience Inc2002-03-19Not applicableCanada
PMS-prednisolone Sod Phos Oph Sol Forte 1%Solution / drops1 %OphthalmicPharmascience Inc1992-12-31Not applicableCanada
Pred ForteSuspension / drops10 mg/mLOphthalmicAllergan1973-06-01Not applicableUs
Pred ForteSuspension / drops10 mg/mLOphthalmicA S Medication Solutions1973-06-012017-06-20Us
Pred ForteSuspension / drops10 mg/mLOphthalmicA S Medication Solutions1973-06-012017-06-20Us
Pred Forte 1%Solution / drops1 %OphthalmicAllergan1974-12-31Not applicableCanada
Pred MildSuspension / drops1.2 mg/mLOphthalmicAllergan1972-12-01Not applicableUs
Pred MildSuspension / drops1.2 mg/mLOphthalmicPhysicians Total Care, Inc.2012-11-01Not applicableUs
Pred MildSuspension / drops1.2 mg/mLOphthalmicPreferreed Pharmaceuticals Inc.2012-03-05Not applicableUs
Pred Mild 0.12%Solution / drops0.12 %OphthalmicAllergan1974-12-31Not applicableCanada
Prednisolone AcetateSuspension / drops10 mg/mLOphthalmicA S Medication Solutions1994-12-152017-06-20Us
Prednisolone AcetateSuspension10 mg/mLOphthalmicClinical Solutions Wholsesale1994-12-152017-07-01Us
Prednisolone AcetateSuspension / drops10 mg/1OphthalmicRemedy Repack2013-04-122017-02-16Us
Prednisolone AcetateSuspension / drops10 mg/mLOphthalmicA S Medication Solutions1997-08-192017-06-20Us
Prednisolone AcetateSuspension / drops10 mg/mLOphthalmicPacific Pharma1997-08-19Not applicableUs
Prednisolone AcetateSuspension / drops10 mg/mLOphthalmicA S Medication Solutions1994-12-152017-06-20Us
Prednisolone AcetateSuspension / drops10 mg/mLOphthalmicSandoz1994-12-15Not applicableUs
Prednisolone AcetateSuspension / drops10 mg/mLOphthalmicNu Care Pharmaceuticals,inc.1997-08-19Not applicableUs
Prednisolone AcetateSuspension / drops10 mg/mLOphthalmicH.J. Harkins Company1997-08-19Not applicableUs
Prednisolone AcetateSuspension / drops10 mg/mLOphthalmicPreferreed Pharmaceuticals Inc.2012-10-23Not applicableUs
Prednisolone AcetateSuspension10 mg/mLOphthalmicPhysicians Total Care, Inc.2002-11-04Not applicableUs
Prednisolone Acetate Ophthalmic Suspension USP 1%Suspension1 %OphthalmicBausch & Lomb IncNot applicableNot applicableCanada
Prednisolone Sodium PhosphateTablet, orally disintegrating30 mg/1OralPrasco, Laboratories2015-10-21Not applicableUs
Prednisolone Sodium PhosphateSolution5 mg/5mLOralSeton Pharmaceuticals2013-10-18Not applicableUs
Prednisolone Sodium Phosphate 1% ForteLiquid; Solution / drops1 %OphthalmicRivex Ophthalmics Inc.1997-05-072003-07-28Canada
Prednisolone Sodium Phosphate ODTTablet, orally disintegrating15 mg/1OralPrasco, Laboratories2015-10-21Not applicableUs
Prednisolone Sodium Phosphate ODTTablet, orally disintegrating10 mg/1OralPrasco, Laboratories2015-10-21Not applicableUs
R.O.-predphate Tm ForteLiquid; Solution / drops1 %OphthalmicRichmond Pharmaceuticals1992-12-311997-08-11Canada
Ratio-prednisoloneSuspension1 %OphthalmicTeva1986-12-31Not applicableCanada
Sab-prednaseSolution1 %OphthalmicSabex IncNot applicableNot applicableCanada
Sandoz PrednisoloneSuspension0.12 %OphthalmicSandoz Canada Incorporated1993-12-31Not applicableCanada
Sandoz PrednisoloneSuspension1 %OphthalmicSandoz Canada Incorporated1993-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MillipredSolution10 mg/5mLOralLaser Pharmaceuticals Llc2009-07-01Not applicableUs
MillipredTablet5 mg/1OralZylera Pharmaceuticals, LLC2014-03-01Not applicableUs
MillipredSolution10 mg/5mLOralZylera Pharmaceuticals, LLC2014-03-01Not applicableUs
MillipredTablet5 mg/5mgOralLaser Pharmaceuticals Llc2008-10-01Not applicableUs16477 0505 01 nlmimage10 851b42ca
OrapredSolution15 mg/5mLOralShionogi2000-12-142016-02-22Us
PediapredSolution5 mg/5mLOralRoyal Pharmaceuticals2003-03-26Not applicableUs
PrednisoloneSolution15 mg/5mLOralApotheca, Inc.2003-02-27Not applicableUs
PrednisoloneSyrup15 mg/5mLOralPhysicians Total Care, Inc.2003-02-28Not applicableUs
PrednisoloneSyrup15 mg/5mLOralEthex Corporation2004-05-10Not applicableUs
PrednisoloneSolution15 mg/5mLOralAidarex Pharmaceuticals LLC2003-02-27Not applicableUs
PrednisoloneSyrup5 mg/5mLOralPhysicians Total Care, Inc.2003-02-28Not applicableUs
PrednisoloneSolution15 mg/5mLOralAidarex Pharmaceuticals LLC1998-12-11Not applicableUs
PrednisoloneSolution15 mg/5mLOralMed Vantx, Inc.1998-12-11Not applicableUs
PrednisoloneSolution15 mg/5mLOralStat Rx USA2003-02-27Not applicableUs
PrednisoloneSolution15 mg/5mLOralTeva1998-12-11Not applicableUs
PrednisoloneSolution15 mg/5mLOralHi Tech Pharmacal Co., Inc.2003-02-27Not applicableUs
PrednisoloneSyrup15 mg/5mLOralClinical Solutions Wholsesale2007-09-212017-06-24Us
PrednisoloneSolution15 mg/5mLOralPreferreed Pharmaceuticals Inc.2003-02-27Not applicableUs
PrednisoloneSolution15 mg/5mLOralProficient Rx LP2003-02-27Not applicableUs
PrednisoloneSolution15 mg/5mLOralDirectrx2014-01-01Not applicableUs
PrednisoloneSyrup15 mg/5mLOralA S Medication Solutions2007-09-212017-06-20Us
PrednisoloneSolution15 mg/5mLOralA S Medication Solutions2003-02-272017-06-20Us
PrednisoloneSolution15 mg/5mLOralDispensing Solutions, Inc.2003-02-27Not applicableUs
PrednisoloneSolution15 mg/5mLOralRebel Distributors2003-02-27Not applicableUs
PrednisoloneSyrup15 mg/5mLOralPreferreed Pharmaceuticals Inc.2013-10-25Not applicableUs
PrednisoloneSyrup15 mg/5mLOralQualitest2007-09-21Not applicableUs
Prednisolone Sodium PhosphateSolution15 mg/5mLOralPharmaceutical Associates, Inc.2005-04-25Not applicableUs
Prednisolone Sodium PhosphateSolution15 mg/5mLOralA S Medication Solutions2004-10-042017-06-20Us
Prednisolone Sodium PhosphateSolution5 mg/5mLOralHi Tech Pharmacal Co., Inc.2003-03-26Not applicableUs
Prednisolone Sodium PhosphateSolution10 mg/5mLOralPharmaceutical Associates, Inc.2017-01-31Not applicableUs
Prednisolone Sodium PhosphateSolution15 mg/5mLOralAmneal Pharmaceuticals of New York Llc2009-12-01Not applicableUs
Prednisolone Sodium PhosphateSolution5 mg/5mLOralA S Medication Solutions2003-03-262017-06-20Us
Prednisolone Sodium PhosphateTablet, orally disintegrating15 mg/1OralMylan Pharmaceuticals2014-12-08Not applicableUs
Prednisolone Sodium PhosphateSolution20 mg/5mLOralEdenbridge Pharmaceuticals Llc2016-12-21Not applicableUs
Prednisolone Sodium PhosphateSolution15 mg/5mLOralQualitest2009-05-262017-02-16Us
Prednisolone Sodium PhosphateSolution15 mg/5mLOralProficient Rx LP2005-04-25Not applicableUs
Prednisolone Sodium PhosphateSolution15 mg/5mLOralA S Medication Solutions2005-04-252017-06-20Us
Prednisolone Sodium PhosphateSolution5 mg/5mLOralSeton Pharmaceuticals2003-03-26Not applicableUs
Prednisolone Sodium PhosphateSolution15 mg/5mLOralPhysicians Total Care, Inc.2005-03-03Not applicableUs
Prednisolone Sodium PhosphateSolution20 mg/5mLOralPharmaceutical Associates, Inc.2017-01-31Not applicableUs
Prednisolone Sodium PhosphateSolution15 mg/5mLOralAtlantic Biologicals Corps.2005-04-25Not applicableUs
Prednisolone Sodium PhosphateTablet, orally disintegrating30 mg/1OralMylan Pharmaceuticals2014-12-08Not applicableUs
Prednisolone Sodium PhosphateSolution15 mg/5mLOralRebel Distributors2009-12-01Not applicableUs
Prednisolone Sodium PhosphateSolution / drops10 mg/mLOphthalmicButler Animal Health Supply1994-07-29Not applicableUs
Prednisolone Sodium PhosphateTablet, orally disintegrating10 mg/1OralMylan Pharmaceuticals2014-12-08Not applicableUs
Prednisolone Sodium PhosphateSolution10 mg/5mLOralEdenbridge Pharmaceuticals Llc2016-12-21Not applicableUs
Prednisolone Sodium PhosphateSolution15 mg/5mLOralUnit Dose Services2005-04-25Not applicableUs
Prednisolone Sodium PhosphateSolution / drops10 mg/mLOphthalmicMwi/Vet One1994-07-29Not applicableUs
Prednisolone Sodium PhosphateSolution15 mg/5mLOralCardinal Health2004-10-04Not applicableUs
Prednisolone Sodium PhosphateSolution15 mg/5mLOralMorton Grove Pharmaceuticals, Inc.2004-10-04Not applicableUs
Prednisolone Sodium PhosphateSolution15 mg/5mLOralRed Pharm Drug, Inc.2005-04-25Not applicableUs
Prednisolone Sodium PhosphateSolution / drops10 mg/mLOphthalmicBauch & Lomb Incorporated1994-07-29Not applicableUs
Prednisolone Sodium Phosphate Oral SolutionSolution25 mg/5mLOralMission Pharmacal2012-10-01Not applicableUs
Veripred 20Solution20 mg/5mLOralZylera Pharmaceuticals, LLC2014-08-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Ak-PredNot Available
Decortin HNot Available
Delta-CortefNot Available
DeltacortrilNot Available
HydeltraNot Available
Hydeltra-TBANot Available
HydeltrasolNot Available
InflamaseNot Available
Key-PredNot Available
KlismacortNot Available
MeticorteloneNot Available
PanafcorteloneNot Available
PrecortalonNot Available
PredonineNot Available
PreloneNot Available
SoloneNot Available
SteroloneNot Available
UltracortenolNot Available
Brand mixtures
NameLabellerIngredients
BlephamideAllergan
Blephamide Oph OntAllergan
Blephamide Opht SuspensionAllergan
Dioptimyd OintmentDioptic Pharmaceuticals Inc
Metimyd Oph SusSchering Plough
Odan-cideOdan Laboratories Ltd
Pred-GAllergan
Prednisolone/sulfacetamideEberth Pharmaceuticals Inc
Sulfacetamide Sodium and Prednisolone Sodium PhosphateRebel Distributors
Vasocidin Ophthalmic SolutionIolab Pharmaceuticals
Categories
UNII9PHQ9Y1OLM
CAS number50-24-8
WeightAverage: 360.444
Monoisotopic: 360.193674006
Chemical FormulaC21H28O5
InChI KeyOIGNJSKKLXVSLS-VWUMJDOOSA-N
InChI
InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
IUPAC Name
(1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES
[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[[email protected]](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Pharmacology
Indication

For the treatment of primary or secondary adrenocortical insufficiency, such as congenital adrenal hyperplasia, thyroiditis. Also used to treat psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, bursitis, acute gouty arthritis and epicondylitis. Also indicated for treatment of systemic lupus erythematosus, pemphigus and acute rhematic carditis. Can be used in the treatment of leukemias, lymphomas, thrombocytopenia purpura and autoimmune hemolytic anemia. Can be used to treat celiac disease, insulin resistance, ulcerative colitis and liver disorders.

Structured Indications
Pharmacodynamics

Prednisolone is a synthetic glucocorticoid used as antiinflammatory or immunosuppressive agent. Prednisolone is indicated in the treatment of various conditions, including congenital adrenal hyperplasia, psoriatic arthritis, systemic lupus erythematosus, bullous dermatitis herpetiformis, seasonal or perennial allergic rhinitis, allergic corneal marginal ulcers, symptomatic sarcoidosis, idiopathic thrombocytopenic purpura in adults, leukemias and lymphomas in adults, and ulcerative colitis. Glucocorticoids are adrenocortical steroids and cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.

Mechanism of action

Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.

TargetKindPharmacological actionActionsOrganismUniProt ID
Glucocorticoid receptorProteinyes
agonist
HumanP04150 details
Related Articles
Absorption

Readily absorbed by gastrointestinal tract, peak plasma concentration is reached 1-2 hours after administration.

Volume of distributionNot Available
Protein binding

Very high (>90%)

Metabolism

Excreted in the urine as either free or glucoconjugate.

Route of eliminationNot Available
Half life

2-3 hours

ClearanceNot Available
Toxicity

LD50=500 mg/kg (oral, rat), short-term side effects include high blood glucose levels and fluid retention. Long term side effects include Cushing's syndrome, weight gain, osteoporosis, glaucoma, type II diabetes and adrenal suppression.

Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Prednisolone is combined with 1,10-Phenanthroline.Experimental
2,4-thiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Prednisolone.Investigational
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Prednisolone.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Prednisolone.Approved
AcetaminophenThe serum concentration of Prednisolone can be increased when it is combined with Acetaminophen.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Prednisolone.Withdrawn
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Prednisolone.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Prednisolone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Prednisolone.Approved
AfatinibThe serum concentration of Prednisolone can be increased when it is combined with Afatinib.Approved
AICA ribonucleotideThe therapeutic efficacy of Aicar can be decreased when used in combination with Prednisolone.Experimental
AlbendazoleThe serum concentration of Prednisolone can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinPrednisolone may decrease the antineoplastic activities of Aldesleukin.Approved
AldosteroneThe serum concentration of Prednisolone can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Prednisolone can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Prednisolone can be increased when it is combined with Alfentanil.Approved, Illicit
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Prednisolone.Approved
Aluminum hydroxideThe bioavailability of Prednisolone can be decreased when combined with Aluminum hydroxide.Approved
AmantadineThe serum concentration of Prednisolone can be increased when it is combined with Amantadine.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Prednisolone is combined with Ambenonium.Approved
Aminohippuric acidThe serum concentration of Prednisolone can be increased when it is combined with Aminohippuric acid.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Prednisolone.Approved
AmiodaroneThe metabolism of Prednisolone can be decreased when combined with Amiodarone.Approved, Investigational
AmiodaroneThe serum concentration of Prednisolone can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Prednisolone can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Prednisolone can be increased when it is combined with Amlodipine.Approved
Amphotericin BPrednisolone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Prednisolone can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Prednisolone can be increased when it is combined with Amsacrine.Approved
AndrographolideThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Prednisolone.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Prednisolone.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Prednisolone.Approved
ApocyninThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Prednisolone.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Prednisolone.Approved, Investigational
AprepitantThe serum concentration of Prednisolone can be increased when it is combined with Aprepitant.Approved, Investigational
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Prednisolone resulting in a loss in efficacy.Approved
AstemizoleThe serum concentration of Prednisolone can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Prednisolone can be decreased when combined with Atazanavir.Approved, Investigational
AtazanavirThe serum concentration of Prednisolone can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Prednisolone can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Prednisolone can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Prednisolone can be increased when it is combined with Atorvastatin.Approved
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Prednisolone.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Prednisolone.Withdrawn
AzelastineThe serum concentration of Prednisolone can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Prednisolone can be increased when it is combined with Azithromycin.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Prednisolone.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Prednisolone.Approved, Investigational
BazedoxifeneThe serum concentration of Prednisolone can be increased when it is combined with Bazedoxifene.Approved, Investigational
BCG vaccineThe therapeutic efficacy of Bcg can be decreased when used in combination with Prednisolone.Investigational
BendroflumethiazidePrednisolone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Prednisolone.Withdrawn
BenzocaineThe serum concentration of Prednisolone can be increased when it is combined with Benzocaine.Approved
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Prednisolone.Approved
BepridilThe serum concentration of Prednisolone can be increased when it is combined with Bepridil.Approved, Withdrawn
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Prednisolone.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Prednisolone.Approved, Investigational
BexaroteneThe serum concentration of Prednisolone can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe serum concentration of Prednisolone can be increased when it is combined with Biperiden.Approved
Bismuth SubcitrateThe bioavailability of Prednisolone can be decreased when combined with Bismuth Subcitrate.Approved
BoceprevirThe metabolism of Prednisolone can be decreased when combined with Boceprevir.Withdrawn
BoceprevirThe serum concentration of Prednisolone can be increased when it is combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Prednisolone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Prednisolone can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Prednisolone can be increased when it is combined with Bosutinib.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Prednisolone.Approved
BromocriptineThe serum concentration of Prednisolone can be increased when it is combined with Bromocriptine.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Prednisolone.Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Prednisolone.Withdrawn
BumetanidePrednisolone may increase the hypokalemic activities of Bumetanide.Approved
BuprenorphineThe serum concentration of Prednisolone can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Prednisolone can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Prednisolone.Approved
CaffeineThe serum concentration of Prednisolone can be increased when it is combined with Caffeine.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Prednisolone.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Prednisolone can be decreased when combined with Calcium carbonate.Approved
CanagliflozinThe serum concentration of Prednisolone can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Prednisolone can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Prednisolone can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Prednisolone can be increased when combined with Carbamazepine.Approved, Investigational
CarbamazepineThe serum concentration of Prednisolone can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbimazoleThe serum concentration of Prednisolone can be decreased when it is combined with Carbimazole.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Prednisolone.Approved, Vet Approved, Withdrawn
CarvedilolThe serum concentration of Prednisolone can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Prednisolone can be increased when it is combined with Caspofungin.Approved
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Prednisolone.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Prednisolone.Approved, Investigational
CeritinibThe serum concentration of Prednisolone can be increased when it is combined with Ceritinib.Approved
ChloroquineThe serum concentration of Prednisolone can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazidePrednisolone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Prednisolone can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorpromazineThe serum concentration of Prednisolone can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Prednisolone can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Prednisolone can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidonePrednisolone may increase the hypokalemic activities of Chlorthalidone.Approved
CholesterolThe serum concentration of Prednisolone can be increased when it is combined with Cholesterol.Experimental
CholestyramineCholestyramine can cause a decrease in the absorption of Prednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cholic AcidThe serum concentration of Prednisolone can be decreased when it is combined with Cholic Acid.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Prednisolone.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Prednisolone.Experimental
CilazaprilThe serum concentration of Prednisolone can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Prednisolone can be decreased when it is combined with Cimetidine.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Prednisolone can be increased when it is combined with Citalopram.Approved
ClarithromycinThe metabolism of Prednisolone can be decreased when combined with Clarithromycin.Approved
ClarithromycinThe serum concentration of Prednisolone can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Prednisolone can be decreased when combined with Clemastine.Approved
ClofazimineThe serum concentration of Prednisolone can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Prednisolone can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Prednisolone.Approved
ClotrimazoleThe metabolism of Prednisolone can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Prednisolone can be decreased when combined with Cobicistat.Approved
CobicistatThe serum concentration of Prednisolone can be increased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Prednisolone can be increased when it is combined with Colchicine.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Prednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Prednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColforsinThe serum concentration of Prednisolone can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Prednisolone can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Prednisolone can be increased when it is combined with Conjugated Equine Estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Prednisolone.Approved
CrizotinibThe metabolism of Prednisolone can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Prednisolone.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Prednisolone.Approved, Investigational
CyclosporineThe metabolism of Prednisolone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Prednisolone.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Prednisolone can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Prednisolone can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Prednisolone can be increased when it is combined with Dactinomycin.Approved
DarunavirThe metabolism of Prednisolone can be decreased when combined with Darunavir.Approved
DarunavirThe serum concentration of Prednisolone can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Prednisolone can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Prednisolone can be decreased when it is combined with Daunorubicin.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Prednisolone is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Prednisolone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Prednisolone can be decreased when combined with Delavirdine.Approved
DemecariumThe risk or severity of adverse effects can be increased when Prednisolone is combined with Demecarium.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Prednisolone.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Prednisolone.Investigational
DesipramineThe serum concentration of Prednisolone can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Prednisolone.Approved
DesloratadineThe serum concentration of Prednisolone can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Prednisolone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Prednisolone can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Prednisolone can be increased when it is combined with Diclofenac.Approved, Vet Approved
DienestrolThe serum concentration of Prednisolone can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Prednisolone can be increased when it is combined with Diethylstilbestrol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Prednisolone.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Prednisolone.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Prednisolone.Approved
DihydroergotamineThe metabolism of Prednisolone can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteronePrednisolone may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DiltiazemThe metabolism of Prednisolone can be decreased when combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Prednisolone can be increased when it is combined with Dipyridamole.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Prednisolone.Approved, Investigational
DonepezilThe risk or severity of adverse effects can be increased when Prednisolone is combined with Donepezil.Approved
DoxazosinThe serum concentration of Prednisolone can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Prednisolone can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Prednisolone can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Prednisolone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Prednisolone can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Prednisolone can be decreased when combined with Dronedarone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Prednisolone.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Prednisolone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Prednisolone.Investigational
E-6201The risk or severity of adverse effects can be increased when E6201 is combined with Prednisolone.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Prednisolone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Prednisolone is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Prednisolone is combined with Edrophonium.Approved
EfavirenzThe serum concentration of Prednisolone can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Prednisolone can be increased when it is combined with Elbasvir.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Prednisolone.Approved
EnalaprilThe serum concentration of Prednisolone can be increased when it is combined with Enalapril.Approved, Vet Approved
EnoxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Prednisolone can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Prednisolone.Approved
EquolThe serum concentration of Prednisolone can be increased when it is combined with S Equol.Investigational
ErgonovineThe serum concentration of Prednisolone can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Prednisolone can be increased when it is combined with Ergotamine.Approved
ErythromycinThe metabolism of Prednisolone can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Prednisolone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstradiolThe serum concentration of Prednisolone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Prednisolone can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Prednisolone can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Prednisolone can be increased when it is combined with Estrone.Approved
Etacrynic acidPrednisolone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Prednisolone.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Prednisolone can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Prednisolone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Prednisolone.Approved
EtoposideThe serum concentration of Prednisolone can be increased when it is combined with Etoposide.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Prednisolone.Approved, Investigational
EtravirineThe serum concentration of Prednisolone can be decreased when it is combined with Etravirine.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Prednisolone.Approved, Investigational
FelodipineThe serum concentration of Prednisolone can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Prednisolone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Prednisolone.Approved
FentanylThe serum concentration of Prednisolone can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Prednisolone can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Prednisolone can be increased when it is combined with Fidaxomicin.Approved
FingolimodPrednisolone may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Prednisolone.Approved, Withdrawn
FluconazoleThe metabolism of Prednisolone can be decreased when combined with Fluconazole.Approved
FlumequineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Flumequine.Withdrawn
FluoxetineThe serum concentration of Prednisolone can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluoxymesteronePrednisolone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlupentixolThe serum concentration of Prednisolone can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Prednisolone can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Prednisolone can be increased when it is combined with Flurazepam.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Prednisolone.Approved, Investigational
FluvoxamineThe metabolism of Prednisolone can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Prednisolone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Prednisolone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Prednisolone can be increased when combined with Fosphenytoin.Approved
FosphenytoinThe serum concentration of Prednisolone can be decreased when it is combined with Fosphenytoin.Approved
FurosemidePrednisolone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Prednisolone can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Prednisolone is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Prednisolone is combined with Gallamine Triethiodide.Approved
GatifloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Gatifloxacin.Approved, Investigational
GefitinibThe serum concentration of Prednisolone can be increased when it is combined with Gefitinib.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Prednisolone can be increased when it is combined with Genistein.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Prednisolone is combined with Ginkgo biloba.Approved, Nutraceutical
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Prednisolone.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Prednisolone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Prednisolone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Prednisolone.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Prednisolone.Approved
GlyburideThe serum concentration of Prednisolone can be increased when it is combined with Glyburide.Approved
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Prednisolone.Approved
Gramicidin DThe serum concentration of Prednisolone can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Grepafloxacin.Withdrawn
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Prednisolone.Investigational
HaloperidolThe serum concentration of Prednisolone can be increased when it is combined with Haloperidol.Approved
HexestrolThe serum concentration of Prednisolone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Prednisolone.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Prednisolone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Prednisolone.Approved, Investigational
HydrochlorothiazidePrednisolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe serum concentration of Prednisolone can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazidePrednisolone may increase the hypokalemic activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Prednisolone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Prednisolone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Prednisolone.Approved
IdelalisibThe serum concentration of Prednisolone can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Prednisolone can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Prednisolone can be increased when it is combined with Imipramine.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Prednisolone.Approved
IndapamidePrednisolone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe metabolism of Prednisolone can be decreased when combined with Indinavir.Approved
IndinavirThe serum concentration of Prednisolone can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Prednisolone can be increased when it is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Prednisolone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Prednisolone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Prednisolone is combined with INGN 225.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Prednisolone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Prednisolone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Prednisolone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Prednisolone.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Prednisolone.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Prednisolone.Approved
IsavuconazoniumThe metabolism of Prednisolone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Prednisolone is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Prednisolone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Prednisolone.Withdrawn
IsradipineThe metabolism of Prednisolone can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Prednisolone can be decreased when combined with Itraconazole.Approved, Investigational
ItraconazoleThe serum concentration of Prednisolone can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Prednisolone can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Prednisolone can be increased when it is combined with Ivermectin.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Prednisolone.Experimental
KetamineThe serum concentration of Prednisolone can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe metabolism of Prednisolone can be decreased when combined with Ketoconazole.Approved, Investigational
KetoconazoleThe serum concentration of Prednisolone can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Prednisolone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Prednisolone.Approved
LansoprazoleThe serum concentration of Prednisolone can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Prednisolone can be increased when it is combined with Lapatinib.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Prednisolone is combined with Leflunomide.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Levofloxacin.Approved, Investigational
LevothyroxineThe serum concentration of Prednisolone can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Prednisolone can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Prednisolone.Approved
LiothyronineThe serum concentration of Prednisolone can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Prednisolone can be decreased when it is combined with Liotrix.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Prednisolone.Approved
LisinoprilThe serum concentration of Prednisolone can be increased when it is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Prednisolone.Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Lomefloxacin.Approved
LomitapideThe serum concentration of Prednisolone can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Prednisolone can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Prednisolone can be decreased when combined with Lopinavir.Approved
LopinavirThe serum concentration of Prednisolone can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Prednisolone can be increased when it is combined with Loratadine.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Prednisolone.Approved
LosartanThe serum concentration of Prednisolone can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Prednisolone can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Prednisolone.Approved
LuliconazoleThe serum concentration of Prednisolone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Prednisolone can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Prednisolone.Approved, Investigational
MagaldrateThe bioavailability of Prednisolone can be decreased when combined with Magaldrate.Withdrawn
Magnesium carbonateThe bioavailability of Prednisolone can be decreased when combined with Magnesium carbonate.Approved
Magnesium HydroxideThe bioavailability of Prednisolone can be decreased when combined with Magnesium hydroxide.Approved
Magnesium oxideThe bioavailability of Prednisolone can be decreased when combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Prednisolone.Approved
Magnesium TrisilicateThe bioavailability of Prednisolone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Prednisolone is combined with Malathion.Approved, Investigational
MaprotilineThe serum concentration of Prednisolone can be increased when it is combined with Maprotiline.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Prednisolone.Approved
MebendazoleThe serum concentration of Prednisolone can be increased when it is combined with Mebendazole.Approved, Vet Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Prednisolone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Prednisolone.Approved
MefloquineThe serum concentration of Prednisolone can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Prednisolone can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Prednisolone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Memantine.Approved, Investigational
MeprobamateThe serum concentration of Prednisolone can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Prednisolone.Approved
MestranolThe serum concentration of Prednisolone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Prednisolone.Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Prednisolone.Approved
MethadoneThe serum concentration of Prednisolone can be increased when it is combined with Methadone.Approved
MethallenestrilThe serum concentration of Prednisolone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Prednisolone is combined with Methanesulfonyl Fluoride.Investigational
MethimazoleThe serum concentration of Prednisolone can be decreased when it is combined with Methimazole.Approved
MethyclothiazidePrednisolone may increase the hypokalemic activities of Methyclothiazide.Approved
MethyltestosteronePrednisolone may increase the fluid retaining activities of Methyltestosterone.Approved
MetolazonePrednisolone may increase the hypokalemic activities of Metolazone.Approved
MetoprololThe serum concentration of Prednisolone can be increased when it is combined with Metoprolol.Approved, Investigational
MibefradilThe serum concentration of Prednisolone can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Prednisolone can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Prednisolone can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe therapeutic efficacy of Prednisolone can be decreased when used in combination with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Prednisolone.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Prednisolone.Approved
MinaprineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Minaprine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Prednisolone.Approved, Investigational
MitomycinThe serum concentration of Prednisolone can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Prednisolone can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Prednisolone can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MivacuriumMivacurium may increase the adverse neuromuscular activities of Prednisolone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Prednisolone.Investigational
ModafinilThe serum concentration of Prednisolone can be decreased when it is combined with Modafinil.Approved, Investigational
MorphineThe serum concentration of Prednisolone can be increased when it is combined with Morphine.Approved, Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Prednisolone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Prednisolone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Prednisolone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Prednisolone.Approved, Investigational
NafcillinThe serum concentration of Prednisolone can be decreased when it is combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Prednisolone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Prednisolone is combined with Nalidixic Acid.Approved
NaltrexoneThe serum concentration of Prednisolone can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Prednisolone.Approved, Vet Approved
NaringeninThe serum concentration of Prednisolone can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Prednisolone is combined with Natalizumab.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Prednisolone.Approved, Investigational
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Prednisolone.Investigational
NefazodoneThe metabolism of Prednisolone can be decreased when combined with Nefazodone.Approved, Withdrawn
NefazodoneThe serum concentration of Prednisolone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Prednisolone can be decreased when combined with Nelfinavir.Approved
NelfinavirThe serum concentration of Prednisolone can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Prednisolone can be increased when it is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Prednisolone.Approved
NetupitantThe serum concentration of Prednisolone can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Prednisolone can be increased when combined with Nevirapine.Approved
NevirapineThe serum concentration of Prednisolone can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Prednisolone can be increased when it is combined with Nicardipine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Prednisolone is combined with Nicorandil.Approved
NifedipineThe serum concentration of Prednisolone can be decreased when it is combined with Nifedipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Prednisolone.Approved
NilotinibThe metabolism of Prednisolone can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Prednisolone.Approved, Withdrawn
NisoldipineThe serum concentration of Prednisolone can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Prednisolone can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Prednisolone can be increased when it is combined with Nitrendipine.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Prednisolone.Investigational
NorethisteroneThe serum concentration of Prednisolone can be decreased when it is combined with Norethisterone.Approved
NorfloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Norfloxacin.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Ofloxacin.Approved
OlaparibThe metabolism of Prednisolone can be decreased when combined with Olaparib.Approved
OleandrinAnvirzel may decrease the cardiotoxic activities of Prednisolone.Experimental
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Prednisolone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Prednisolone.Approved
OmeprazoleThe serum concentration of Prednisolone can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Prednisolone can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Prednisolone.Approved
OxandrolonePrednisolone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Prednisolone.Approved
OxymetholonePrednisolone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Prednisolone.Withdrawn
P-NitrophenolThe serum concentration of Prednisolone can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Prednisolone.Approved, Vet Approved
PalbociclibThe serum concentration of Prednisolone can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Prednisolone can be increased when it is combined with Palmitic Acid.Experimental
PantoprazoleThe serum concentration of Prednisolone can be increased when it is combined with Pantoprazole.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Prednisolone.Approved
ParoxetineThe serum concentration of Prednisolone can be increased when it is combined with Paroxetine.Approved, Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Pefloxacin.Approved
PentobarbitalThe metabolism of Prednisolone can be increased when combined with Pentobarbital.Approved, Vet Approved
PentobarbitalThe serum concentration of Prednisolone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerindoprilThe serum concentration of Prednisolone can be increased when it is combined with Perindopril.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Prednisolone.Approved, Withdrawn
PhenobarbitalThe metabolism of Prednisolone can be increased when combined with Phenobarbital.Approved
PhenobarbitalThe serum concentration of Prednisolone can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Prednisolone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Prednisolone.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Prednisolone.Approved, Investigational
PhenytoinThe metabolism of Prednisolone can be increased when combined with Phenytoin.Approved, Vet Approved
PhenytoinThe serum concentration of Prednisolone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Prednisolone.Approved, Investigational
PimozideThe serum concentration of Prednisolone can be increased when it is combined with Pimozide.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Prednisolone.Approved, Investigational
PiretanidePrednisolone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Prednisolone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Prednisolone.Approved, Investigational
Platelet Activating FactorThe serum concentration of Prednisolone can be decreased when it is combined with Platelet Activating Factor.Experimental
PolythiazidePrednisolone may increase the hypokalemic activities of Polythiazide.Approved
PonatinibThe serum concentration of Prednisolone can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe metabolism of Prednisolone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PosaconazoleThe serum concentration of Prednisolone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Prednisolone.Approved, Investigational
PravastatinThe serum concentration of Prednisolone can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Prednisolone can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Prednisolone can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimidoneThe metabolism of Prednisolone can be increased when combined with Primidone.Approved, Vet Approved
PrimidoneThe serum concentration of Prednisolone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Prednisolone can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Prednisolone can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromestrieneThe serum concentration of Prednisolone can be increased when it is combined with Promestriene.Investigational
PromethazineThe serum concentration of Prednisolone can be increased when it is combined with Promethazine.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Prednisolone.Approved
PropafenoneThe serum concentration of Prednisolone can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Prednisolone can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Prednisolone can be increased when it is combined with Protriptyline.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Prednisolone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Pyridostigmine.Approved
QuercetinThe serum concentration of Prednisolone can be increased when it is combined with Quercetin.Experimental
QuinacrineThe serum concentration of Prednisolone can be increased when it is combined with Quinacrine.Approved
QuinestrolThe serum concentration of Prednisolone can be increased when it is combined with Quinestrol.Approved
QuinethazonePrednisolone may increase the hypokalemic activities of Quinethazone.Approved
QuinidineThe serum concentration of Prednisolone can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Prednisolone can be increased when it is combined with Quinine.Approved
RanitidineThe serum concentration of Prednisolone can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Prednisolone can be increased when it is combined with Ranolazine.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Prednisolone.Withdrawn
ReboxetineThe serum concentration of Prednisolone can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Prednisolone can be increased when it is combined with Regorafenib.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Prednisolone.Approved, Investigational
ReserpineThe serum concentration of Prednisolone can be decreased when it is combined with Reserpine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Prednisolone.Experimental, Investigational
RifabutinThe metabolism of Prednisolone can be increased when combined with Rifabutin.Approved
RifabutinThe serum concentration of Prednisolone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe metabolism of Prednisolone can be increased when combined with Rifampicin.Approved
RifampicinThe serum concentration of Prednisolone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Prednisolone can be increased when combined with Rifapentine.Approved
RifapentineThe serum concentration of Prednisolone can be decreased when it is combined with Rifapentine.Approved
RilpivirineThe serum concentration of Prednisolone can be increased when it is combined with Rilpivirine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Prednisolone is combined with CDX-110.Investigational
RitonavirThe serum concentration of Prednisolone can be increased when it is combined with Ritonavir.Approved, Investigational
RitonavirThe metabolism of Prednisolone can be decreased when combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Prednisolone.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Prednisolone.Approved
RolapitantThe serum concentration of Prednisolone can be increased when it is combined with Rolapitant.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Prednisolone.Approved, Investigational
RosoxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Rosoxacin.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Prednisolone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Prednisolone.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Prednisolone.Approved
SaquinavirThe metabolism of Prednisolone can be decreased when combined with Saquinavir.Approved, Investigational
SaquinavirThe serum concentration of Prednisolone can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Prednisolone.Approved
ScopolamineThe serum concentration of Prednisolone can be increased when it is combined with Scopolamine.Approved
SecoisolariciresinolThe serum concentration of Prednisolone can be increased when it is combined with Secoisolariciresinol.Investigational
SelegilineThe serum concentration of Prednisolone can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SertralineThe serum concentration of Prednisolone can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Prednisolone can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Prednisolone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Prednisolone can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Prednisolone can be increased when it is combined with Simvastatin.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Prednisolone.Approved
SirolimusThe serum concentration of Prednisolone can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Prednisolone.Approved, Investigational
SorafenibThe serum concentration of Prednisolone can be increased when it is combined with Sorafenib.Approved, Investigational
SparfloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Sparfloxacin.Approved
SpironolactoneThe serum concentration of Prednisolone can be increased when it is combined with Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Prednisolone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Prednisolone.Investigational
St. John's WortThe serum concentration of Prednisolone can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololPrednisolone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StaurosporineThe serum concentration of Prednisolone can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Prednisolone can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Prednisolone can be decreased when it is combined with Streptozocin.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Prednisolone.Approved
SulfinpyrazoneThe serum concentration of Prednisolone can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Prednisolone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Prednisolone.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Prednisolone.Approved, Investigational
SumatriptanThe serum concentration of Prednisolone can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Prednisolone can be increased when it is combined with Sunitinib.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Prednisolone.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Prednisolone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Prednisolone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe serum concentration of Prednisolone can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Prednisolone.Approved, Investigational
TacrolimusThe serum concentration of Prednisolone can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Prednisolone can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Prednisolone can be increased when it is combined with Taurocholic Acid.Experimental
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Prednisolone.Withdrawn
TelaprevirThe serum concentration of Prednisolone can be increased when it is combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Prednisolone can be decreased when combined with Telithromycin.Approved
TelithromycinThe serum concentration of Prednisolone can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Prednisolone can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Temafloxacin.Withdrawn
TemsirolimusThe serum concentration of Prednisolone can be increased when it is combined with Temsirolimus.Approved
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Prednisolone.Approved
TerazosinThe serum concentration of Prednisolone can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Prednisolone can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Prednisolone.Approved
TesmilifeneThe serum concentration of Prednisolone can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Prednisolone can be increased when it is combined with Testosterone.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Prednisolone.Approved
TiboloneThe serum concentration of Prednisolone can be increased when it is combined with Tibolone.Approved
TicagrelorThe serum concentration of Prednisolone can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Prednisolone can be decreased when combined with Ticlopidine.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Prednisolone.Investigational
TocilizumabThe serum concentration of Prednisolone can be decreased when it is combined with Tocilizumab.Approved
TofacitinibPrednisolone may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Prednisolone.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Prednisolone.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Prednisolone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Prednisolone.Approved
TolvaptanThe serum concentration of Prednisolone can be increased when it is combined with Tolvaptan.Approved
TorasemidePrednisolone may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Prednisolone.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Prednisolone.Approved, Investigational
TrazodoneThe serum concentration of Prednisolone can be decreased when it is combined with Trazodone.Approved, Investigational
TrichlormethiazidePrednisolone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe serum concentration of Prednisolone can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Prednisolone can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Prednisolone can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Prednisolone can be increased when it is combined with Trimipramine.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Prednisolone.Withdrawn
TrovafloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Prednisolone.Investigational, Withdrawn
VenlafaxineThe metabolism of Prednisolone can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Prednisolone can be decreased when combined with Verapamil.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Prednisolone.Approved, Investigational
VinblastineThe serum concentration of Prednisolone can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Prednisolone can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Prednisolone can be increased when it is combined with Vinorelbine.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Prednisolone.Approved, Investigational
VoriconazoleThe metabolism of Prednisolone can be decreased when combined with Voriconazole.Approved, Investigational
VoriconazoleThe serum concentration of Prednisolone can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinPrednisolone may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Prednisolone.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Prednisolone.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Prednisolone can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Prednisolone can be decreased when combined with Ziprasidone.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Prednisolone.Withdrawn
Food Interactions
  • Avoid alcohol. Avoid caffeine.
  • Take with food to reduce gastric irritation.
References
Synthesis Reference

Gunther Bellmann, "Process for producing a sterile prednisolone gel." U.S. Patent US5811417, issued September 22, 1998.

US5811417
General ReferencesNot Available
External Links
ATC CodesS02BA03 — PrednisoloneD07AA03 — PrednisoloneR01AD52 — Prednisolone, combinationsS01CA02 — Prednisolone and antiinfectivesV03AB05 — Prednisolone and promethazineS01CB02 — PrednisoloneD07CA03 — Prednisolone and antibioticsD07XA02 — PrednisoloneA07EA01 — PrednisoloneC05AA04 — PrednisoloneS03BA02 — PrednisoloneA01AC54 — Prednisolone, combinationsS02CA01 — Prednisolone and antiinfectivesR01AD02 — PrednisoloneS03CA02 — Prednisolone and antiinfectivesH02AB06 — PrednisoloneS01BB02 — Prednisolone and mydriaticsS01BA04 — PrednisoloneD07BA01 — Prednisolone and antiseptics
AHFS Codes
  • 52:08.08
  • 68:04.00
PDB EntriesNot Available
FDA labelDownload (101 KB)
MSDSDownload (72.6 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingDiagnosticSevere Alcoholic Hepatitis1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers / Pharmacodynamics / Pharmacokinetics / Rheumatoid Arthritis / Safety / Tolerability1
1CompletedBasic ScienceHealthy Volunteers / Pulmonary Disease, Chronic Obstructive1
1CompletedBasic ScienceImmunoscience1
1CompletedOtherInflammatory Reaction1
1CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
1CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD) / Pulmonary Disease, Chronic Obstructive1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentMalignant Neoplasm of Prostate1
1CompletedTreatmentMultiple Myeloma (MM)1
1CompletedTreatmentPulmonary Disease, Chronic Obstructive1
1RecruitingPreventionEsophageal Anastomotic Stricture1
1RecruitingTreatmentRheumatoid Arthritis1
1RecruitingTreatmentStatus Asthmaticus1
1TerminatedTreatmentAsthma Bronchial1
1TerminatedTreatmentFollicular Lymphoma (FL)1
1Unknown StatusTreatmentLymphoma, Hodgkins1
1Unknown StatusTreatmentMalignant Lymphomas1
1Unknown StatusTreatmentMalignant Lymphomas / Small Intestine Cancer1
1, 2Active Not RecruitingTreatmentLymphoma, B-Cell, Non-Hodgkin's Lymphoma / Non Hodgkin Lymphoma (NHL)1
1, 2Active Not RecruitingTreatmentMalignant Neoplasm of Prostate1
1, 2CompletedBasic ScienceHealthy Volunteers1
1, 2CompletedTreatmentAnaplastic Large Cell Lymphoma, ALK-Negative / Angioimmunoblastic T Cell Lymphoma / Cutaneous T Cell Lymphomas (CTCL) / Peripheral T Cell Lymphoma Unspecified1
1, 2CompletedTreatmentLipomas1
1, 2CompletedTreatmentLymphoma, B-Cell / Lymphoma, Large-Cell, Diffuse1
1, 2CompletedTreatmentMalignant Neoplasm of Prostate1
1, 2CompletedTreatmentNon-Infectious Anterior Uveitis1
1, 2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2Unknown StatusTreatmentMalignant Lymphomas1
2Active Not RecruitingSupportive CareLymphoma, Large B-Cell, Diffuse (DLBCL)1
2Active Not RecruitingSupportive CareMalignant Tumor of Breast / Neoplasm of the Breast / Oral Mucositis / Vesicular Stomatitis1
2Active Not RecruitingTreatmentDuchenne's Muscular Dystrophy (DMD)1
2Active Not RecruitingTreatmentLymphoproliferative Disorders1
2Active Not RecruitingTreatmentMalignant Lymphomas1
2Active Not RecruitingTreatmentMalignant Neoplasm of Prostate1
2Active Not RecruitingTreatmentSteroids In Management Of Acute Asthma Exacerbations1
2CompletedNot AvailableAsthma Bronchial1
2CompletedBasic ScienceCataracts1
2CompletedBasic ScienceWhole Body Catabolisme Induced by Glucocorticoids1
2CompletedPreventionBullous Keratopathy / Fuchs' Dystrophy1
2CompletedPreventionMacular Edema (ME)1
2CompletedSupportive CarePostoperative pain / Prophylaxis against postoperative nausea and vomiting1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2CompletedTreatmentAlcoholic Hepatitis (AH)1
2CompletedTreatmentBronchial Asthma1
2CompletedTreatmentConjunctivitis, Seasonal Allergic1
2CompletedTreatmentConnective Tissue Diseases / Dermatomyositis / Vasculitis / Vasculitis, Hypersensitivity1
2CompletedTreatmentGranulomatosis With Polyangiitis / Microscopic Polyangiitis / Renal Limited Vasculitis1
2CompletedTreatmentHIV Disease Progression1
2CompletedTreatmentHansen's Disease2
2CompletedTreatmentHormone Refractory / Malignant Neoplasm of Prostate / Metastatic1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
2CompletedTreatmentLeukemias1
2CompletedTreatmentLymphoma, B-Cell1
2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2CompletedTreatmentMacular Edema After Cataract Surgery in Patients With Diabetes Mellitus1
2CompletedTreatmentMalignant Lymphomas3
2CompletedTreatmentMalignant Lymphomas / Neurotoxicity1
2CompletedTreatmentMalignant Neoplasm of Prostate2
2CompletedTreatmentMalignant Neoplasm of Prostate / Metastatic Cancers1
2CompletedTreatmentNephritis, Lupus2
2CompletedTreatmentNon-Infectious Anterior Uveitis1
2CompletedTreatmentRheumatoid Arthritis4
2Enrolling by InvitationPreventionIritis1
2Not Yet RecruitingTreatmentIatrogenic Cushing's Disease1
2RecruitingTreatmentAcute Interstitial Nephritis1
2RecruitingTreatmentAcute Leukemias of Ambiguous Lineage / Childhood B Acute Lymphoblastic Leukemia / KMT2A Gene Rearrangement / Mixed Phenotype Acute Leukemia (MPAL)1
2RecruitingTreatmentAlcoholic Hepatitis (AH)1
2RecruitingTreatmentAnaplastic Large Cell Lymphoma, ALK-Negative / Angioimmunoblastic T-Cell Lymphoma / Hepatosplenic Gamma/ Delta T-cell Lymphoma / Peripheral T-cell Lymphoma NOS1
2RecruitingTreatmentAutoimmune Diseases1
2RecruitingTreatmentCerebral Radiation Necrosis1
2RecruitingTreatmentEpstein-Barr Virus-positive Diffuse Large B-cell Lymphoma1
2RecruitingTreatmentKaposiform Hemangioendothelioma / Kasabach Merritt Phenomenon1
2RecruitingTreatmentLPL Deficiency1
2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2RecruitingTreatmentStage II Childhood Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
2SuspendedTreatmentAllergic Alveolitis1
2TerminatedBasic ScienceDependence, Cocaine / Opioid Dependence1
2TerminatedTreatmentHemangiomas2
2TerminatedTreatmentHemangiomas of Infancy1
2TerminatedTreatmentLymphoma, Lymphoblastic1
2TerminatedTreatmentMultiple Myeloma (MM)1
2TerminatedTreatmentOsteoarthritis of the Knees1
2Unknown StatusTreatmentCancer, Breast1
2Unknown StatusTreatmentChronic Renal Insufficiency / Transplantation, Liver1
2Unknown StatusTreatmentLeukemias3
2Unknown StatusTreatmentLymphoblastic Leukemia, Acute1
2Unknown StatusTreatmentMalignant Lymphomas2
2Unknown StatusTreatmentMalignant Lymphomas / Small Intestine Cancer1
2Unknown StatusTreatmentStomatitis, Aphthous1
2, 3Active Not RecruitingTreatmentRetinal Vein Occlusions(RVO)1
2, 3CompletedDiagnosticRheumatoid Arthritis1
2, 3CompletedTreatmentAspergillosis, Allergic Bronchopulmonary2
2, 3CompletedTreatmentGluten Enteropathy1
2, 3CompletedTreatmentHansen's Disease1
2, 3CompletedTreatmentInfertilities1
2, 3CompletedTreatmentPolymyalgia Rheumatica1
2, 3Not Yet RecruitingTreatmentIgA Nephropathy1
2, 3RecruitingTreatmentMalignant Neoplasm of Prostate1
2, 3Unknown StatusTreatmentAnkylosing Spondylitis (AS)1
3Active Not RecruitingTreatmentDrug/Agent Toxicity by Tissue/Organ / Leukemias1
3Active Not RecruitingTreatmentFollicular Lymphoma (FL)1
3Active Not RecruitingTreatmentLymphoma, B-Cell / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
3Active Not RecruitingTreatmentMalignant Lymphomas1
3Active Not RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer1
3Active Not RecruitingTreatmentMultiple Myeloma (MM)1
3Active Not RecruitingTreatmentProgression of Rheumatoid Arthritis1
3Active Not RecruitingTreatmentProstatic Neoplasms1
3CompletedNot AvailableUveitis1
3CompletedBasic ScienceCataracts1
3CompletedPreventionTransplantation, Kidney1
3CompletedTreatmentActive Rheumatoid Arthritis1
3CompletedTreatmentAlcoholic Hepatitis (AH) / Severe alcoholic liver disease1
3CompletedTreatmentAllergic Rhinitis (AR)1
3CompletedTreatmentAnemia, Hemolytic, Autoimmune1
3CompletedTreatmentAsthma Bronchial2
3CompletedTreatmentAsthma Bronchial / Wheezing1
3CompletedTreatmentCancers / Carcinoma NOS / Malignant Ascites / Neoplasms1
3CompletedTreatmentCataracts / Inflammatory Reaction1
3CompletedTreatmentCataracts / Non-Proliferative Diabetic Retinopathy2
3CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
3CompletedTreatmentDermatomyositis / Polymyositis1
3CompletedTreatmentEndogenous Anterior Uveitis1
3CompletedTreatmentEye Infections / Postoperative Complications1
3CompletedTreatmentGlomerulonephritis, Membranous1
3CompletedTreatmentGlomerulonephritis, Membranous / Glomerulosclerosis, Focal Segmental1
3CompletedTreatmentGlomerulonephritis, Membranous / Nephritis, Lupus1
3CompletedTreatmentHeadaches1
3CompletedTreatmentHemangiomas1
3CompletedTreatmentHepatocellular,Carcinoma1
3CompletedTreatmentIdiopathic Thrombocytopenic Purpura (ITP)1
3CompletedTreatmentInfantile Spasms (IS) / West Syndrome1
3CompletedTreatmentInfection and Inflammation After Refractive Surgery (Lasik)1
3CompletedTreatmentLeukemias3
3CompletedTreatmentLeukemias / Malignant Lymphomas2
3CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
3CompletedTreatmentMalignant Lymphomas4
3CompletedTreatmentMultiple Myeloma (MM)1
3CompletedTreatmentMyasthenia Gravis1
3CompletedTreatmentProstatic Neoplasms1
3CompletedTreatmentTransplantation, Renal1
3CompletedTreatmentTuberculous Pericarditis1
3CompletedTreatmentUlcerative Colitis (UC)1
3Not Yet RecruitingSupportive CarePulpitis dental1
3Not Yet RecruitingTreatmentB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / BCR-ABL1 Fusion Protein Expression / Minimal Residual Disease / Philadelphia Chromosome Positive / T Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Not Yet RecruitingTreatmentImmune Thrombocytopenia1
3Not Yet RecruitingTreatmentInfantile Spasms (IS)1
3Not Yet RecruitingTreatmentMature B-cell Non-Hodgkin Lymphoma1
3RecruitingPreventionAcute Urinary Tract Infection / Urinary Tract Infections (UTIs)1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic1
3RecruitingTreatmentAlcoholic Hepatitis (AH) / Severe alcoholic liver disease1
3RecruitingTreatmentAnterior Uveitis (AU)1
3RecruitingTreatmentAsthma Bronchial1
3RecruitingTreatmentCataracts1
3RecruitingTreatmentCongenital Adrenal Hyperplasia (CAH)1
3RecruitingTreatmentGlomerulonephritis minimal lesion1
3RecruitingTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
3RecruitingTreatmentImmuoglobulin / Mucocutaneous Lymph Node Syndrome / Steroid1
3SuspendedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3SuspendedTreatmentSystemic Lupus Erythematosus, Lupus Nephritis1
3TerminatedHealth Services ResearchFollicular Lymphoma (FL)1
3TerminatedTreatmentCrohn's Disease (CD)1
3TerminatedTreatmentCutaneous Hypersensitivity1
3TerminatedTreatmentDiscal Sciatica1
3TerminatedTreatmentEvidence of Liver Transplantation / Transplantations1
3TerminatedTreatmentMalignant Lymphomas1
3TerminatedTreatmentNephritis, Lupus1
3TerminatedTreatmentPemphigus1
3TerminatedTreatmentUlcerative Colitis (UC)1
3Unknown StatusTreatmentAcute Exacerbation of Chronic Obstructive Pulmonary Disease1
3Unknown StatusTreatmentAlcoholic Hepatitis (AH)1
3Unknown StatusTreatmentAllergic Rhinitis (AR)1
3Unknown StatusTreatmentBiliary Atresia1
3Unknown StatusTreatmentDermatitis, Contact / Dermatitis, Seborrheic / Moderate, refractory Atopic dermatitis / Psoriasis1
3Unknown StatusTreatmentFollicular Lymphoma (FL)1
3Unknown StatusTreatmentInfantile Spasms (IS)1
3Unknown StatusTreatmentLeukemias1
3Unknown StatusTreatmentLeukemias / Malignant Lymphomas1
3Unknown StatusTreatmentLymphoblastic Leukemia, Acute1
3Unknown StatusTreatmentMalignant Lymphomas4
3Unknown StatusTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
3Unknown StatusTreatmentRheumatoid Arthritis1
3Unknown StatusTreatmentDiffuse posterior uveitis1
3WithdrawnTreatmentNephritis, Lupus1
4Active Not RecruitingTreatmentConjunctivitis, Giant Papillary / Conjunctivitis, Seasonal Allergic / Inflammatory Reaction1
4Active Not RecruitingTreatmentCorneal Transplant / Grafting, Corneal / Keratoplasty, Lamellar / Transplantation, Cornea / Transplantation, Corneal1
4Active Not RecruitingTreatmentMCNS / Minimal Change Nephrotic Syndrome (MCNS)1
4Active Not RecruitingTreatmentMalignant Neoplasm of Prostate1
4Active Not RecruitingTreatmentRheumatoid Arthritis1
4Active Not RecruitingTreatmentSeasonal Allergic Rhinitis (SAR)1
4CompletedNot AvailableAsthma Bronchial1
4CompletedNot AvailableCataract operation1
4CompletedNot AvailableMacula Thickening1
4CompletedPreventionCataracts1
4CompletedPreventionChronic Allergic Conjunctivitis1
4CompletedPreventionConjunctivitis, Seasonal Allergic1
4CompletedPreventionCorneal Edema / Fuchs' Dystrophy1
4CompletedPreventionRenal Transplanted Recipients1
4CompletedPreventionTracheal Stenosis1
4CompletedPreventionTransplantation, Kidney1
4CompletedTreatmentAcute Asthma / Asthma Bronchial / Reactive Airway Exacerbation1
4CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
4CompletedTreatmentAdult Acute Lymphocytic Leukemia3
4CompletedTreatmentAsthma Bronchial3
4CompletedTreatmentBell's Palsy1
4CompletedTreatmentBurkitt's Lymphoma / Large Cell Anaplastic Lymphoma / Lymphoma, Lymphoblastic / Mediastinal Neoplasms1
4CompletedTreatmentCataract operation1
4CompletedTreatmentCataracts2
4CompletedTreatmentCataracts / Corneal Edema / Retinal Structural Change, Deposit and Degeneration / Visual Acuity Reduced Transiently1
4CompletedTreatmentCataracts / Dry Eye Syndromes1
4CompletedTreatmentCataracts / Glaucoma1
4CompletedTreatmentChronic Diseases / Idiopathic eosinophilic pneumonias1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4CompletedTreatmentConjunctivitis, Seasonal Allergic1
4CompletedTreatmentGlaucoma1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentHemangiomas1
4CompletedTreatmentLymphoma, Lymphoblastic1
4CompletedTreatmentMalignant Neoplasm of Prostate1
4CompletedTreatmentMeibomian Gland Dysfunction (MGD)1
4CompletedTreatmentMetastatic Hormone Refractory Prostate Cancer1
4CompletedTreatmentOptic Disk / Regional Blood Flow1
4CompletedTreatmentOral Lichen Planus1
4CompletedTreatmentPain1
4CompletedTreatmentPolyps, Nasal1
4CompletedTreatmentPulpitis dental1
4CompletedTreatmentRejection, Transplant / Renal Failure / Transplantation, Kidney1
4CompletedTreatmentRenal Function1
4CompletedTreatmentRheumatoid Arthritis1
4CompletedTreatmentSepsis1
4CompletedTreatmentModerate, refractory Atopic dermatitis1
4Enrolling by InvitationTreatmentCrohn's Disease (CD)1
4Not Yet RecruitingTreatmentAsthma Bronchial / Status Asthmaticus / Wheezing1
4Not Yet RecruitingTreatmentCystoid Macular Edema / Macular Edema (ME) / Uveitis1
4Not Yet RecruitingTreatmentGlomerulonephritis minimal lesion1
4Not Yet RecruitingTreatmentUlcerative Colitis (UC)1
4RecruitingDiagnosticCoughing1
4RecruitingPreventionEsophageal Strictures / Esophagus, Barrett1
4RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
4RecruitingTreatmentAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Granulomatosis With Polyangiitis / Microscopic Polyangiitis1
4RecruitingTreatmentBlood Eosinophil Count / Chronic Obstructive Pulmonary Disease (COPD) / Glucocorticoid therapy / Lung Diseases, Obstructive / Pulmonary Disease, Chronic Obstructive1
4RecruitingTreatmentChoroidal Effusions / Glaucoma1
4RecruitingTreatmentDrug Interaction Potentiation / Transplantation, Kidney1
4RecruitingTreatmentEpilepsy, Unspecified, Intractable1
4RecruitingTreatmentFulminant Hepatic Failure1
4RecruitingTreatmentFunction of Renal Transplant1
4RecruitingTreatmentGlomerulonephritis minimal lesion2
4RecruitingTreatmentIgA Nephropathy1
4RecruitingTreatmentImmunoglobulin G4 Related Sclerosing Disease1
4RecruitingTreatmentInfertilities / Polycystic Ovarian Syndrome1
4RecruitingTreatmentMalignant Lymphomas1
4RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer1
4RecruitingTreatmentMycoplasma Pneumoniae Pneumonia1
4RecruitingTreatmentOphthalmopathy, Thyroid-Associated1
4RecruitingTreatmentPsychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
4RecruitingTreatmentRecurrent IgA Nephropathy1
4RecruitingTreatmentRheumatoid Arthritis2
4RecruitingTreatmentVestibular Diseases / Vestibular Neuronitis1
4TerminatedTreatmentImmune Reconstitution Inflammatory Syndrome / Progressive Multifocal Leukoencephalopathy1
4TerminatedTreatmentObstructive Sleep Apnea Syndrome (OSAS)1
4Unknown StatusPreventionCataract operation / Pseudophakia1
4Unknown StatusTreatmentAdult Acute Lymphocytic Leukemia2
4Unknown StatusTreatmentCataracts1
4Unknown StatusTreatmentChronic Hepatitis B Infection1
4Unknown StatusTreatmentCrohn's Disease (CD)1
4Unknown StatusTreatmentDisorder Related to Renal Transplantation1
4Unknown StatusTreatmentWheezing1
Not AvailableActive Not RecruitingBasic ScienceAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD)1
Not AvailableActive Not RecruitingTreatmentMalignant Lymphomas1
Not AvailableCompletedNot AvailableHemangiomas1
Not AvailableCompletedBasic ScienceElectroretinography1
Not AvailableCompletedPreventionBeta-cell Function / Diabetes Mellitus (DM) / Glucocorticoid-induced Diabetes / Steroid Diabetes1
Not AvailableCompletedPreventionEpiretinal Membrane1
Not AvailableCompletedPreventionPatients With Systemic Inflammatory Diseases Receiving for the First Time a Protracted General Corticostroid Therapy1
Not AvailableCompletedTreatmentBiliary Atresia1
Not AvailableCompletedTreatmentCarpal Tunnel Syndrome (CTS)1
Not AvailableCompletedTreatmentChildhood Langerhans Cell Histiocytosis1
Not AvailableCompletedTreatmentCorneal Neovascularization1
Not AvailableCompletedTreatmentFacial Paralysis1
Not AvailableCompletedTreatmentGlaucoma1
Not AvailableCompletedTreatmentGlaucoma, Primary Open Angle (POAG) / Pseudoexfoliation Syndrome1
Not AvailableCompletedTreatmentGlucocorticoid-induced Beta-cell Dysfunction / Glucocorticoid-induced Glucometabolic Abnormalities1
Not AvailableCompletedTreatmentGlucose tolerance impaired / Hyperglycemias / Insulin Resistance1
Not AvailableCompletedTreatmentIgA Nephropathy1
Not AvailableCompletedTreatmentModerate to Severe Atopic Dermatitis1
Not AvailableCompletedTreatmentReproductive Sterility1
Not AvailableCompletedTreatmentScleral Buckling1
Not AvailableCompletedTreatmentTuberculous Pleurisy1
Not AvailableRecruitingNot AvailableDegeneration / Ectasia / Keratoconus2
Not AvailableRecruitingNot AvailableIgA Nephropathy / Immunosuppressive Treatment / Proteinuria in Nephrotic Range1
Not AvailableRecruitingHealth Services ResearchHypospadias1
Not AvailableRecruitingTreatmentCorneal Graft Rejection1
Not AvailableTerminatedNot AvailableProstatic Neoplasms1
Not AvailableTerminatedTreatmentDrug Induced Liver Injury1
Not AvailableTerminatedTreatmentOpen Angle Glaucoma (OAG)1
Not AvailableUnknown StatusNot AvailableAsthma Exacerbations1
Not AvailableUnknown StatusNot AvailableScleritis / Uveitis1
Not AvailableUnknown StatusPreventionAsthma Bronchial1
Not AvailableUnknown StatusSupportive CareNon-Hodgkin's Lymphoma (NHL)1
Not AvailableUnknown StatusTreatmentBehcet's Syndrome / Uveal Disease1
Not AvailableUnknown StatusTreatmentBell's Palsy1
Not AvailableUnknown StatusTreatmentLeukemias2
Not AvailableUnknown StatusTreatmentMalignant Lymphomas3
Not AvailableWithdrawnNot AvailableLeukemias1
Not AvailableWithdrawnTreatmentBronchiolitis1
Pharmacoeconomics
Manufacturers
  • Pharmacia and upjohn co
  • Akorn inc
  • Sandoz canada inc
  • Teva parenteral medicines inc
  • Watson laboratories inc
  • Bel mar laboratories inc
  • Schering corp sub schering plough corp
  • Alpharma uspd inc
  • Apotex inc richmond hill
  • Hi tech pharmacal co inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Kv pharmaceutical co
  • Pharmaceutical assoc inc div beach products
  • Teva pharmaceuticals usa
  • Vintage pharmaceuticals llc
  • We pharmaceuticals inc
  • Wockhardt eu operations (swiss) ag
  • Muro pharmaceutical inc
  • Teva pharmaceuticals usa inc
  • Halsey drug co inc
  • Ferndale laboratories inc
  • Barr laboratories inc
  • Cm bundy co
  • Elkins sinn div ah robins co inc
  • Everylife
  • John j ferrante
  • Heather drug co inc
  • Impax laboratories inc
  • Inwood laboratories inc sub forest laboratories inc
  • Lannett co inc
  • Marshall pharmacal corp
  • Panray corp sub ormont drug and chemical co inc
  • L perrigo co
  • Phoenix laboratories inc
  • Purepac pharmaceutical co
  • Private formulations inc
  • Roxane laboratories inc
  • Sandoz inc
  • Sperti drug products inc
  • Superpharm corp
  • Tablicaps inc
  • Udl laboratories inc
  • Valeant pharmaceuticals international
  • Vitarine pharmaceuticals inc
  • West ward pharmaceutical corp
  • Whiteworth towne paulsen inc
  • Pfizer laboratories div pfizer inc
  • Central pharmaceuticals inc
  • Alcon laboratories inc
  • Allergan pharmaceutical
  • Taro pharmaceuticals usa inc
  • Merck and co inc
  • Novartis pharmaceuticals corp
  • Pharmafair inc
  • Alcon universal ltd
  • Bausch and lomb pharmaceuticals inc
  • Sola barnes hind
  • Shionogi pharma inc
  • Ucb inc
  • Amneal pharmaceuticals
  • Paddock laboratories inc
  • Pharmaceutical assoc inc
Packagers
Dosage forms
FormRouteStrength
OintmentOphthalmic
Suspension / dropsOphthalmic
Solution / dropsOphthalmic
OintmentOphthalmic; Topical
SuspensionOral15 mg/5mL
LiquidOphthalmic10 mg
SolutionOphthalmic1 %
LiquidOphthalmic.125 %
LiquidOphthalmic1.25 mg
SuspensionOphthalmic
SolutionOral10 mg/5mL
TabletOral5 mg/1
TabletOral5 mg/5mg
Solution / dropsOphthalmic; Topical0.5 %
TabletOral5 mg
LiquidOral5 mg
SolutionOral5 mg
Solution / dropsOphthalmic1 %
Suspension / dropsOphthalmic1.2 mg/mL
Solution / dropsOphthalmic0.12 %
SyrupOral15 mg/5mL
SyrupOral5 mg/5mL
SuspensionOphthalmic10 mg/mL
Suspension / dropsOphthalmic10 mg/1
Suspension / dropsOphthalmic10 mg/mL
SolutionOral15 mg/5mL
SolutionOral5 mg/5mL
Solution / dropsOphthalmic10 mg/mL
Tablet, orally disintegratingOral10 mg/1
Tablet, orally disintegratingOral15 mg/1
Tablet, orally disintegratingOral30 mg/1
SolutionOral25 mg/5mL
Liquid; solution / dropsOphthalmic1 %
SuspensionOphthalmic0.12 %
SuspensionOphthalmic1 %
SolutionOphthalmic
LiquidOphthalmic
SolutionOral20 mg/5mL
Prices
Unit descriptionCostUnit
Orapred ODT 48 15 mg Dispersible Tablet Box289.42USD box
Pred Forte 1% Suspension 15ml Bottle97.79USD bottle
PrednisoLONE Sodium Phosphate 1% Solution 10ml Bottle72.82USD bottle
Pred Forte 1% Suspension 10ml Bottle68.06USD bottle
Econopred Plus 1% Suspension 10ml Bottle63.44USD bottle
Solu-Medrol Act-O-Vial 1 g/vial61.25USD vial
Solu-Medrol 1 g/vial60.04USD vial
Pediapred 6.7 mg/5ml Solution 120ml Bottle57.77USD bottle
Pred Mild 0.12% Suspension 10ml Bottle44.33USD bottle
Econopred Plus 1% Suspension 5ml Bottle40.99USD bottle
Solu-Medrol Act-O-Vial 500 mg/vial39.96USD vial
Medrol (Pak) 21 4 mg tablet Disp Pack39.3USD disp
Solu-Medrol 500 mg/vial39.17USD vial
Pred Forte 1% Suspension 5ml Bottle37.12USD bottle
Prednisolone sod ph powder36.11USD g
PrednisoLONE Acetate 1% Suspension 15ml Bottle35.46USD bottle
PrednisoLONE Sodium Phosphate 1% Solution 15ml Bottle34.41USD bottle
Pred Mild 0.12% Suspension 5ml Bottle33.98USD bottle
Methylprednisolone Sod Succin. 1 g/vial32.47USD vial
Solu-medrol 1 gm vial24.43USD vial
PrednisoLONE Acetate 1% Suspension 10ml Bottle24.02USD bottle
Solu-medrol (pf) 500 mg vial20.9USD vial
PrednisoLONE Sodium Phosphate 1% Solution 5ml Bottle19.99USD bottle
Methylprednisolone Sod Succin. 500 mg/vial19.48USD vial
PrednisoLONE Acetate 1% Suspension 5ml Bottle15.99USD bottle
Solu-Medrol Act-O-Vial 125 mg/vial15.94USD vial
Solu-medrol 500 mg vial12.9USD vial
Depo-medrol 80 mg/ml vial11.67USD ml
Depo-Medrol 80 mg/ml11.51USD ml
Pred forte 1% eye drops10.32USD ml
Methylprednisolone Acetate 80 mg/ml9.01USD ml
Methylprednisolone Sod Succin. 125 mg/vial8.9USD vial
Depo-Medrol (Preserved) 80 mg/ml8.89USD ml
Orapred odt 30 mg tablet8.34USD tablet
Orapred odt 15 mg tablet7.97USD tablet
Methylprednisolone Acetate (P) 80 mg/ml6.97USD ml
Omnipred 1% eye drops6.78USD ml
Solu-Medrol Act-O-Vial 40 mg/vial6.72USD vial
Depo-medrol 40 mg/ml vial6.41USD ml
Depo-Medrol 40 mg/ml6.01USD ml
Pred Forte 1 % Suspension5.95USD ml
Solu-medrol (pf) 125 mg vial5.83USD vial
Depo-Medrol (Preserved) 40 mg/ml5.75USD ml
Prednisolone ac 1% eye drop5.75USD ml
Prednisol 1% eye drops5.69USD ml
Pred mild 0.12% eye drops5.14USD ml
Medrol 32 mg tablet5.13USD tablet
Methylprednisolone Acetate 40 mg/ml4.71USD ml
Methylprednisolone Acetate (P) 40 mg/ml4.5USD ml
Econopred plus 1% eye drops3.93USD ml
Orapred odt 10 mg tablet3.89USD tablet
Depo-medrol 20 mg/ml vial3.78USD ml
Methylprednisolone Sod Succin. 40 mg/vial3.77USD vial
Prednisolone sod 1% eye drops3.7USD ml
Medrol 16 mg tablet3.5USD tablet
Prednisolone acetate powder3.36USD g
Prednisolone powder3.36USD g
Depo-Medrol 20 mg/ml2.63USD ml
Medrol 8 mg tablet2.3USD tablet
Ratio-Prednisolone 1 % Suspension2.03USD ml
Sandoz Prednisolone Acetate 1 % Suspension2.03USD ml
Pred Mild 0.12 % Suspension2.02USD ml
Medrol 4 mg tablet1.69USD tablet
Medrol 4 mg dosepak1.59USD each
Sandoz Prednisolone Acetate 0.12 % Suspension1.33USD ml
Millipred dp 5 mg dose pack tablet1.18USD tablet
Medrol 2 mg tablet0.84USD tablet
Orapred 15 mg/5 ml solution0.74USD ml
Millipred 5 mg tablet0.59USD tablet
Prelone 15 mg/5 ml syrup0.54USD ml
Prelone 15 mg/5ml Syrup0.47USD ml
PrednisoLONE Sodium Phosphate 15 mg/5ml Solution0.33USD ml
PrednisoLONE Sodium Phosphate 5 mg/5ml Solution0.23USD ml
Prednisolone 5 mg tablet0.14USD tablet
Pediapred 1 mg/ml Liquid0.14USD ml
Pms-Prednisolone 1 mg/ml Liquid0.07USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5178878 No1993-01-122010-01-12Us
US5881926 No1996-03-162016-03-16Us
US6024981 No1998-04-092018-04-09Us
US6071523 No1998-06-032018-06-03Us
US6221392 No1998-04-092018-04-09Us
US6399079 No1998-06-032018-06-03Us
US6656482 No1998-06-032018-06-03Us
US6740341 No1999-11-242019-11-24Us
US7799331 No2008-10-112028-10-11Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point (°C)235 °CPhysProp
water solubility223 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.62HANSCH,C ET AL. (1995)
logS-3.21ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.239 mg/mLALOGPS
logP1.66ALOGPS
logP1.27ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)12.58ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity98.49 m3·mol-1ChemAxon
Polarizability38.78 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9918
Blood Brain Barrier+0.9383
Caco-2 permeable-0.5096
P-glycoprotein substrateSubstrate0.7861
P-glycoprotein inhibitor INon-inhibitor0.7847
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.7463
CYP450 2C9 substrateNon-substrate0.8496
CYP450 2D6 substrateNon-substrate0.9138
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.9406
CYP450 2C9 inhibitorNon-inhibitor0.9072
CYP450 2D6 inhibitorNon-inhibitor0.9418
CYP450 2C19 inhibitorNon-inhibitor0.9253
CYP450 3A4 inhibitorNon-inhibitor0.8902
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9095
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9597
BiodegradationNot ready biodegradable0.925
Rat acute toxicity1.8914 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.95
hERG inhibition (predictor II)Non-inhibitor0.584
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-0006-0019000000-34782b355045c38d0504View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-002f-0009000000-4a00ac3c2f4930e108ccView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-0005-0689000000-b0eaba9949ae34d0e571View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-00dj-0900000000-0a92fbafb31c0170151cView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-00dj-0900000000-856481c7f4d3a6d1ac63View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-00dj-0900000000-813955b7791f046a3a67View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-00di-0900000000-c70a1009bba6e4f3a2c8View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-0006-0009000000-e4bce0d078573494d8cdView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-006w-0905000000-94eb00e6ffa4c56ac51bView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-00dj-0900000000-7797dc6be351391cf57aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-00dj-0900000000-d156992d517e46c9575dView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-00r2-0910000000-598b90f7f0f7ba4e13ebView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-00di-0900000000-eed30fed077e1dfffd3bView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-002f-0009000000-0af4f657def15fe9274eView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-03di-1920000000-5811b59a6f57222762d7View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-06xw-2910000000-84fec77617e1b7a1648bView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-03dl-0596000000-e0abadaf09054d046b08View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-03xu-0595000000-4f8d30df506ea649fc04View in MoNA
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-006x-1986000000-d088900fa4c56b9ff51dView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassHydroxysteroids
Direct Parent21-hydroxysteroids
Alternative ParentsGluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 3-oxo delta-1,4-steroids / 17-hydroxysteroids / 11-beta-hydroxysteroids / Delta-1,4-steroids / Tertiary alcohols / Alpha-hydroxy ketones / Secondary alcohols / Cyclic ketones
SubstituentsProgestogin-skeleton / 21-hydroxysteroid / 20-oxosteroid / Pregnane-skeleton / 3-oxo-delta-1,4-steroid / 3-oxosteroid / Oxosteroid / 11-beta-hydroxysteroid / 11-hydroxysteroid / 17-hydroxysteroid
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors11beta-hydroxy steroid, 17alpha-hydroxy steroid, glucocorticoid, 20-oxo steroid, 3-oxo-Delta(1),Delta(4)-steroid, 21-hydroxy steroid (CHEBI:8378 ) / Pregnane and derivatives [Fig] (C07369 ) / C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives (LMST02030179 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Uniprot Name:
Glucocorticoid receptor
Molecular Weight:
85658.57 Da
References
  1. Ikonomidis I, Tzortzis S, Lekakis J, Paraskevaidis I, Andreadou I, Nikolaou M, Kaplanoglou T, Katsimbri P, Skarantavos G, Soucacos P, Kremastinos DT: Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis. Heart. 2009 Sep;95(18):1502-7. doi: 10.1136/hrt.2009.168971. Epub 2009 May 28. [PubMed:19482847 ]
  2. Boudinot FD, D'Ambrosio R, Jusko WJ: Receptor-mediated pharmacodynamics of prednisolone in the rat. J Pharmacokinet Biopharm. 1986 Oct;14(5):469-93. [PubMed:2879901 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Uniprot Name:
Cytochrome P450 3A4
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Uniprot Name:
Cytochrome P450 2A6
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Steroid binding
Specific Function:
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name:
SERPINA6
Uniprot ID:
P08185
Uniprot Name:
Corticosteroid-binding globulin
Molecular Weight:
45140.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Frey BM, Frey FJ: Estimation of transcortin concentration by measurements of plasma protein-binding of prednisolone and by electroimmunodiffusion. Br J Clin Pharmacol. 1982 Feb;13(2):245-9. [PubMed:6800390 ]
  4. Ko HC, Almon RR, Jusko WJ: Effect of corticosteroid binding globulin on the pharmacokinetics of prednisolone in rats. Pharm Res. 1995 Jun;12(6):902-4. [PubMed:7667198 ]
  5. Angeli A, Frajria R, De Paoli R, Fonzo D, Ceresa F: Diurnal variation of prednisolone binding to serum corticosteroid-binding globulin in man. Clin Pharmacol Ther. 1978 Jan;23(1):47-53. [PubMed:563315 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Uniprot Name:
Solute carrier organic anion transporter family member 1A2
Molecular Weight:
74144.105 Da
References
  1. Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6. [PubMed:8786566 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Uniprot Name:
Multidrug resistance protein 1
Molecular Weight:
141477.255 Da
References
  1. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019 ]
  2. Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. [PubMed:14661924 ]
Drug created on June 13, 2005 07:24 / Updated on July 23, 2017 12:16